Health Canada has granted approval for Biogen’s Skyclarys (omaveloxolone) to treat Friedreich’s ataxia (FA), a rare, ...

Biogen Canada Inc. is pleased to announce that Health Canada has approved SKYCLARYS™ (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in patients 16 years of age and older.2 This approval ...

As the only approved treatment to address disease progression, SKYCLARYS addresses a long-standing gap in the care of Canadians living with Friedreich's ataxia Friedreich's ...

Careful monitoring of neurologic function, cardiac function, presence of diabetes, monitoring for scoliosis and visual loss ...

PTC Therapeutics could boost revenue with vatiquinone for Friedreich's ataxia. Find out why PTCT stock is poised for growth ...

Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...

Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025Dosing ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich ataxia (FA).

"We are excited to be one step closer to bringing an approved therapy to all patients with Friedreich's ataxia," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics.

The Dunlavin community will gather at the St Nicholas Church of Ireland on March 9 to support local sisters Brona and Helen Kearney at a concert to raise awareness of their rare disease, Friedreich’s ...

Friedreich's ataxia is a rare and life-shortening neuromuscular disorder that affects the central nervous system and the heart. With symptoms typically emerging in childhood or adolescence ...